Foundation Medicine announces $42.5m Series B financing
Foundation Medicine announced Thursday the completion of a $42.5 million Series B financing.
In this round, public crossover funds Deerfield Management Company, L.P., Casdin Capital, Redmile Group and strategic investors Roche Venture Fund and WuXi Corporate Venture Fund joined founding investor Third Rock Ventures and current venture capital backers Google Ventures and Kleiner Perkins Caufield & Byers, Cambridge-based Foundation Medicine said in a press release. In addition to the funds and strategic investors named, there was one undisclosed fund and one undisclosed strategic investor also involved in this financing round.
The company said that its board of directors remains unchanged.
Foundation Medicine describes itself as a molecular information company dedicated to a transformation in cancer care by developing treatments that are informed by an understanding of the genomic changes that contribute to each patient’s unique cancer.
MOST E-MAILED »
- 8 Ways to Give Your Child a Safer Diet
- Medway doctor allegedly wrote bogus prescriptions, shared the drugs with woman
- Public invited on comment to eliminate cash tolling on Tobin Bridge; officials say electronic tolling will reduce congestion, save funds
- Google unveils maps, photo, music features
- Batmobile rolls into town
- Texting makes people weird
- Boy Scouts approve plan to accept openly gay boys
